Lung cancer cells largely exposed to conventional chemotherapy, mainly EGFR-tyrosine kinase inhibitors (TKI) (e.g., gefitinib, erlotinib, and afatinib), acquire stem-like properties that contribute to chemoresistance and tumor relapse in vitro and in vivo. This evidence concerns the gene EGFR and lung carcinoma.